Feasibility of the Switch From Rivastigmine Capsules to Rivastigmine Transdermal Patch: Randomized, Open Label, Controlled Multicenter Study.
Phase of Trial: Phase IV
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Rivastigmine; Rivastigmine
- Indications Alzheimer's disease
- Focus Adverse reactions
- Acronyms KAPA
- Sponsors Novartis
- 23 Mar 2011 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
- 10 Jul 2010 Results presented at the 2010 International Conference on Alzheimer's Disease and Related Disorders.
- 05 Jun 2009 Planned number of patients changed from 144 to 142 as reported by ClinicalTrials.gov.